SYSTEMIC-SCLEROSIS - CURRENT PATHOGENETIC CONCEPTS AND FUTURE-PROSPECTS FOR TARGETED THERAPY

Citation
Cp. Denton et al., SYSTEMIC-SCLEROSIS - CURRENT PATHOGENETIC CONCEPTS AND FUTURE-PROSPECTS FOR TARGETED THERAPY, Lancet, 347(9013), 1996, pp. 1453-1458
Citations number
33
Journal title
LancetACNP
ISSN journal
01406736
Volume
347
Issue
9013
Year of publication
1996
Pages
1453 - 1458
Database
ISI
SICI code
0140-6736(1996)347:9013<1453:S-CPCA>2.0.ZU;2-Z
Abstract
Although there is no cure for systemic sclerosis, the disease is certa inly treatable. And the more that is understood of its pathogenesis, t he better the prospects for treatment. Excessive collagen deposition i n the skin and viscera is responsible for the morbidity and mortality. The immune system plays a critical role in setting up the fibrotic pr ocess, but impaired regulation of collagen gene expression probably un derlies the persistence of fibrosis. The development of effective anti fibrotic drugs, in particular agents that inhibit transcription factor s involved in the activation of type I collagen genes, is likely to be the way forward for treatment of the later stages of diffuse systemic sclerosis, with immunomodulatory therapy for the earlier stages.